Amerikanische Gesellschaft für Hirudotherapie

Preparation and Application of Nanosensor in Safeguarding Heparin Supply Chain

Research article published in SLAS technology (2020)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportSpeichel-PharmakologieKlinische StudienSicherheit & InfektionskontrolleBi Y et al. · SLAS technology, 2020

Abstract

Heparin has been in clinical use as an anticoagulant for the last eight decades and used worldwide in more than 100 million medical procedures every year. This lifesaving drug is predominantly obtained from ~700 million pig intestines or bovine organs through millions of small and medium-sized slaughterhouses. However, the preparations from animal sources have raised many safety concerns, including the contamination of heparin with potential pathogens, proteins, and other impurities. In fact, contaminated heparin preparations caused 149 deaths in several countries, including the United States, Germany, and Japan in 2008, highlighting the need for implementing sensitive and simple analytical techniques to monitor and safeguard the heparin supply chain. The contaminant responsible for the adverse effects in 2008 was identified as oversulfated chondroitin sulfate (OSCS). We have developed a very sensitive, facile method of detecting OSCS in heparin lots using a nanosensor, a gold nanoparticle-heparin dye conjugate. The sensor is an excellent substrate for heparitinase enzyme, which cleaves the heparin polymer into smaller disaccharide fragments, and therefore facilitates recovery of fluorescence from the dye upon heparitinase treatment. However, the presence of OSCS results in diminished fluorescence recovery from the nanosensor upon heparitinase treatment, because OSCS inhibits the enzyme. The newly designed nanosensor can detect as low as 1 × 10-9% (w/w) OSCS, making it the most sensitive tool available to date for the detection of trace amounts of OSCS in pharmaceutical heparins. In this report, we describe a simple methodology for the preparation of nanosensor and its application in the detection of OSCS contaminants.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, N.I.H., Extramural
Indexed MeSH termsBiosensing TechniquesFluorescenceGoldHeparinMetal NanoparticlesNanotechnology

Zusammenfassung

Heparin has been in clinical use as an anticoagulant for the last eight decades and used worldwide in more than 100 million medical procedures every year.

Warum dies für die Hirudotherapie relevant ist

This study describes the development of a gold nanoparticle-heparin dye conjugate nanosensor capable of detecting oversulfated chondroitin sulfate (OSCS) contamination in pharmaceutical heparin at concentrations as low as 1 × 10⁻⁹% (w/w), addressing safety concerns highlighted by the 2008 contaminated heparin crisis that caused 149 deaths. While heparin is an anticoagulant relevant to the broader therapeutic landscape surrounding hirudotherapy, this study involves no leeches, hirudin, or leech-derived components. Its relevance to ASH's domain is only tangential, touching peripherally on anticoagulant drug quality assurance rather than any aspect of leech biology or hirudotherapy practice.

Zitation

Preparation and Application of Nanosensor in Safeguarding Heparin Supply Chain

Bi Y et al. · SLAS technology, 2020

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.